But biomarker enrichment and toxicity remain key for FX-909.
ApexOnco Front Page
Recent articles
The month saw the first commissioner's priority voucher approval in oncology.
But the Japanese group is focused on biliary tract cancer rather than glioblastoma.
On a cross-trial basis varegacestat beats Ogsiveo.
No fewer than four ADCs with this target start human testing.
Some time ago Opdivo beat Adcetris in an NCI trial, and now Bristol files.
Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
The group will start a pivotal trial of samuraciclib following promising second-line results.
